Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Apr 2016)

Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China

  • Chen Jin,
  • Wei Li,
  • Shu‐Bin Qiao,
  • Jin‐Gang Yang,
  • Yang Wang,
  • Pei‐Yuan He,
  • Xin‐Ran Tang,
  • Qiu‐Ting Dong,
  • Xiang‐Dong Li,
  • Hong‐Bing Yan,
  • Yong‐Jian Wu,
  • Ji‐Lin Chen,
  • Run‐Lin Gao,
  • Jin‐Qing Yuan,
  • Ke‐Fei Dou,
  • Bo Xu,
  • Wei Zhao,
  • Xue Zhang,
  • Ying Xian,
  • Yue‐Jin Yang

DOI
https://doi.org/10.1161/JAHA.115.002684
Journal volume & issue
Vol. 5, no. 4

Abstract

Read online

BackgroundTransradial percutaneous coronary intervention (PCI) has been increasingly adopted in clinical practice, given its potential advantages over transfemoral intervention; however, the impact of different access strategies on costs and clinical outcomes remains poorly defined, especially in the developing world. Methods and ResultsUsing data from a consecutive cohort of 5306 patients undergoing PCI in China in 2010, we compared total hospital costs and in‐hospital outcomes for transradial intervention (TRI) and transfemoral intervention. Patients receiving TRI (n=4696, 88.5%) were slightly younger (mean age 57.4 versus 59.5 years), less often women (21.6% versus 33.1%), more likely to undergo PCI for single‐vessel disease, and less likely to undergo PCI for triple‐vessel or left main diseases. The unadjusted total hospital costs were 57 900 Chinese yuan (¥57 900; equivalent to 9190 US dollars [$9190]) for TRI and ¥67 418 ($10,701) for transfemoral intervention. After adjusting for all observed patient and procedural characteristics using the propensity score inverse probability weighting method, TRI was associated with a lower total cost (adjusted difference ¥8081 [$1283]). More than 80% of the cost difference was related to lower PCI‐related costs (adjusted difference −¥5162 [−$819]), which were likely driven by exclusive use of vascular closure devices in transfemoral intervention, and lower hospitalization costs (−¥1399 [−$222]). Patients receiving TRI had shorter length of stay and were less likely to experience major adverse cardiac events or post‐PCI bleeding. These differences were consistent among clinically relevant subgroups with acute myocardial infarction, acute coronary syndrome, and stable angina. ConclusionsAmong patients undergoing PCI, TRI was associated with lower cost and favorable clinical outcomes compared with transfemoral intervention.

Keywords